Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SZV-1287
- Development stage
- Unknown
- Lead developer
- Algonist Biotechnologies
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
SZV-1287 is a small molecule multi-target therapeutic being developed by Algonist Biotechnologies, a portfolio company of CEBINA, for the treatment of neuropathic and chronic pain. The compound, also referred to as ALG-1, functions as a triple inhibitor targeting amine oxidase copper containing 3 (AOC3, also known as semicarbazide-sensitive amine oxidase or SSAO), transient receptor potential ankyrin 1 (TRPA1), and transient receptor potential vanilloid 1 (TRPV1). By inhibiting these targets, SZV-1287 aims to reduce neurogenic inflammation and alleviate pain signaling. It is currently in Phase 1 clinical development, with a single ascending dose study ongoing for neuropathic and chronic pain conditions.
- Other names
- 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)AOC3 (Amine oxidase copper-containing 3)TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on SZV-1287.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SZV-1287.